Florian A. Mann

Florian A. Mann

Auto-generated profile, based on publicly available information

Florian A. Mann

Chemical and Pharmaceutical Development, Bayer Pharmaceuticals

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2018 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
FMFlorian A. Mann
Florian A. Mann
JHJan Horlebein
Jan Horlebein
NMNils Frederik Meyer
Nils Frederik Meyer
DMDaniel Meyer
Daniel Meyer
FTFranziska Thomas
Franziska Thomas
SKSebastian Kruss
Sebastian Kruss

30 October 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
AGAdiran Garaizar
Adiran Garaizar
DDDavid Díaz-Oviedo
David Díaz-Oviedo
NZNina Zablowsky
Nina Zablowsky
SRSami Rissanen
Sami Rissanen
JKJohannes Köbberling
Johannes Köbberling
KMKatharina Meier
Katharina Meier
The use of lipid nanoparticles (LNPs) for therapeutic RNA delivery has gained significant interest, particularly highlighted by recent milestones such as the approval of Onpattro and two mRNA-based SARS-CoV-2 vaccines. However, despite substantial advancements in this field, our understanding of the structure and internal organization of RNA-LNPs –and their relationship to efficacy, both in vitro and in vivo– remains limited. In this study, we present a coarse-grained molecular dynamics (MD) approach that allows for the simulations of full-size LNPs. By analyzing MD-derived structural characteristics in conjunction with cellular experiments, we investigate the effect of critical parameters, such as pH and composition, on LNP structure and potency. Additionally, we examine the mobility and chemical environment within LNPs at a molecular level. Our findings highlight the significant impact that LNP composition and internal molecular mobility can have on key stages of LNP-based intracellular RNA delivery.

27 May 2019 in Nanoscale
Verified
Journal Article
Open access
PDF file
RNRobert Nißler
Robert Nißler
FMFlorian A. Mann
Florian A. Mann
HPHelen Preiß
Helen Preiß
GSGabriele Selvaggio
Gabriele Selvaggio
NHNiklas Herrmann
Niklas Herrmann
SKSebastian Kruss
Sebastian Kruss
Single-walled carbon nanotubes (SWCNTs) have unique photophysical properties and serve as building blocks for biosensors, functional materials and devices. For many applications it is crucial to use chirality-pure SWCNTs, which requires sophisticated processes. Purification procedures such as wrapping by certain polymers, phase separation, density gradient centrifugation or gel chromatography have been developed and yield distinct SWCNT species wrapped by a specific polymer or surfactant. However, many applications require a different organic functionalization (corona) around the SWCNTs instead of the one used for the purification process. Here, we present a novel efficient and straightforward process to gain chirality pure SWCNTs with tunable functionalization. Our approach uses polyfluorene (PFO) polymers to enrich certain chiralities but the polymer is removed again and finally exchanged to any desired organic phase. We demonstrate this concept by dispersing SWCNTs in poly[(9,9-dioctylfluorenyl-2,7-diyl)-alt-co-(6,6′-{2,2′-bipyridine})] (PFO-BPy), which is known to preferentially solubilize (6,5)-SWCNTs. Then PFO-BPy is removed and recycled, while letting the SWCNTs adsorb/agglomerate on sodium chloride (NaCl) crystals, which act as a toluene-stable but water-soluble filler material. In the last step these purified SWCNTs are redispersed in different polymers, surfactants and ssDNA. This corona phase exchange purification (CPEP) approach was also extended to other PFO variants to enrich and functionalize (7,5)-SWCNTs. CPEP purified and functionalized SWCNTs display monodisperse nIR spectra, which are important for fundamental studies and applications that rely on spectral changes. We show this advantage for SWCNT-based nIR fluorescent sensors for the neurotransmitter dopamine and red-shifted sp3 defect peaks . In summary, CPEP makes use of PFO polymers for chirality enrichment but provides access to chirality enriched SWCNTs functionalized in any desired polymer, surfactant or biopolymer.

8 June 2018 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
FMFlorian A. Mann
Florian A. Mann
JHJan Horlebein
Jan Horlebein
NMNils Frederik Meyer
Nils Frederik Meyer
DMDaniel Meyer
Daniel Meyer
FTFranziska Thomas
Franziska Thomas
SKSebastian Kruss
Sebastian Kruss

24 February 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
AGAdiran Garaizar
Adiran Garaizar
DDDavid Díaz-Oviedo
David Díaz-Oviedo
NZNina Zablowsky
Nina Zablowsky
SRSami Rissanen
Sami Rissanen
JKJohannes Köbberling
Johannes Köbberling
KMKatharina Meier
Katharina Meier

8 June 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
JKJosef Kehrein
Josef Kehrein
ERElena Reus
Elena Reus
CHCaroline T. Holick
Caroline T. Holick
SMSebastian Mummel
Sebastian Mummel
IAIlayda Ates
Ilayda Ates
LMLorenz Meinel
Lorenz Meinel
Delivering therapeutic mRNA relies on lipid nanoparticles (LNPs). Finding optimal process parameters for new lipid combinations in LNP formulations remains a challenge. In our work, we used an automated, self-regulating microfluidic platform that actively changes process parameters to tune LNP formulations for preset, desired quality standards. We tested new LNPs by swapping poly(ethylene glycol) (PEG) lipopolymers for alternatives based on poly(2-methyl-2-oxazoline) (PMeOx) and poly(2-ethyl-2-oxazoline) (PEtOx). For each lipopolymer variant, the platform independently identified optimal production conditions in four or fewer iterative cycles, yielding particles of the preset size and high mRNA encapsulation. Small-angle X-ray scattering revealed that smaller LNPs modified with PEtOx had more structural surface variety and higher mRNA loading efficiency. When multiplexing these formulations in mice, the PEtOx-containing LNPs accumulated more in bone marrow compared to those with PEG, indicating trends that the chemistry of the lipopolymer affects the biodistribution of the resulting LNPs. By combining automated formulation and in vivo multiplexed testing, our approach provides a practical way to rapidly plan, formulate, and evaluate large pharmaceutical design spaces, to select excipients and process parameters yielding optimal biological performance of LNPs.